Description: GenSight Biologics S.A., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies for mitochondrial and neurodegenerative diseases of the eye and central nervous system. The company develops its products through gene therapy-based mitochondrial targeting sequence and optogenetics technology platforms. Its lead product candidates include LUMEVOQ (GS010), a recombinant AAV2-based gene therapy, which is in Phase III clinical trials for the treatment of leber hereditary optic neuropathy caused by a mutated ND4 gene; and GS030, which is in Phase I/II clinical trial for the treatment of retinitis pigmentosa, as well as in preclinical stage to treat dry age-related macular degeneration. The company also develops products that are in preclinical stage targeting ophthalmic and neurodegenerative diseases. GenSight Biologics S.A. was incorporated in 2012 and is headquartered in Paris, France.
Home Page: www.gensight-biologics.com
74, rue du Faubourg Saint-Antoine
Paris,
75012
France
Phone:
33 1 76 21 72 20
Officers
| Name | Title |
|---|---|
| Dr. Bernard Gilly Ph.D. | Co-Founder, CEO & Exec. Director |
| Dr. Jose-Alain Sahel M.D., Ph.D. | Scientific Founder, Vice Chairman of Scientific Advisory Board & Board Observer |
| Prof. Botond Roska | Scientific Founder & Chairman of Scientific Advisory Board |
| Dr. Jean E. Bennett M.D., Ph.D. | Scientific Founder & Vice Chairman of Scientific Advisory Board |
| Dr. Luk H. Vandenberghe M.D., Ph.D. | Scientific Founder & Member of Scientific Advisory Board |
| Dr. Serge Picaud | Scientific Founder & Member of Scientific Advisory Board |
| Prof. Constance L. Cepko | Scientific Founder & Member of Scientific Advisory Board |
| Mr. Thomas Gidoin | Chief Financial Officer |
| Mr. Scott Jeffers | Chief Technical Officer |
| Clothilde Caillet | Director of Corp. Communication |
Exchange: PA
Country: FR
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 50.9902 |
| Price-to-Sales TTM: | 33.8105 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 44 |